Clinical impact of CLL epitypes, as determined by Me-iPLEX, at different phases of CLL disease progression and treatment. (A) Kaplan-Meier analysis of TTFT of the Mayo cohort comprising patients sampled at diagnosis separated by epitype. (B) Kaplan-Meier analysis of TTP after uniform treatment with FCR in the MDACC cohort. (C) Cumulative incidence of ibrutinib discontinuation due to CLL progression or RT, from the time of initiating ibrutinib treatment in the OSU-ibrutinib cohort. (D) OS from diagnosis in the Mayo cohort. (E) OS from initiation of therapy in FCR-treated patients from the MDACC cohort. (F) OS from the initiation of ibrutinib therapy in the OSU-ibrutinib cohort. The P values were assessed using the log-rank test.